Roivant Sciences Analyst Price Targets - Benzinga

SPY757.12+0.19%QQQ692.74+0.33%BTC/USD77,589.99+0.20%DIA517.65+0.10%GLD356.15+0.10%TLT81.65−0.23%

Premium Services

Premium Services

Roivant Sciences Ltd

ROIVNASDAQ

Trade with Public

Trade with Public

$36.91

-0.61-1.63%

Last update: Oct 30, 4:32 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Roivant Sciences Analyst Price Targets - Benzinga

Roivant Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Roivant Sciences (ROIV).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

13Buy

1Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$36Upside to Avg. PT-1.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$46→$56
Oct 12, 2026	Wolfe Research	Andy Chen	Downgrade	Outperform→Peer Perform	—
Sep 17, 2026	Stifel	Alex Thompson	Initiate	Buy	$51
Sep 9, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$50→$55
Sep 9, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$42→$46
Sep 8, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$41→$47
Sep 8, 2026	Jefferies	Dennis Ding	PT Raise	Buy	$42→$52
Aug 28, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$41
Aug 10, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$42→$46
Aug 7, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$36→$42
Aug 7, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$34→$41
May 26, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$30→$36
May 21, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$35→$42
May 21, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$38→$41
May 21, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$34
Apr 16, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$22→$40
Mar 4, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$33→$34
Feb 10, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$26→$35
Feb 10, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$26→$33
Feb 9, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$28→$30

Analyst Ratings News

PRO
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56

Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.

Benzinga Newsdesk

This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.

Avi Kapoor

PRO
Wolfe Research Downgrades Roivant Sciences to Peer Perform

Wolfe Research analyst Andy Chen downgrades Roivant Sciences (NASDAQ:ROIV) from Outperform to Peer Perform.

Benzinga Newsdesk

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.

Avi Kapoor

PRO
Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51

Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $51.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55

TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $50 to $55.

Benzinga Newsdesk